ClinicalTrials.gg
CompletedNCT00269412Updated Nov 25, 2019

Study to Assess the Efficacy and Safety of Rifaximin Administered BID in the Treatment of Patients With Diarrhea-Associated Irritable Bowel Syndrome

A Phase 2 interventional study of Rifaximin in Irritable Bowel Syndrome, sponsored by Bausch Health Americas, Inc.. Completed at 67 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-11-25.

Sponsored by Bausch Health Americas, Inc. (part of Bausch Health Companies Inc.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
525
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies testing rifaximin in Irritable Bowel Syndrome — 4 open to participants now, 4 under way, 1 of them phase 3. Rifaximin · Irritable Bowel Syndrome.

Planned enrollment
Largest of 15
525 · median 92
Started
2005
the only one that year
Phase 2
4 of 15
1 open now
Registered
2nd of 15
by date
Lead sponsor
1 of 15
Bausch Health Americas, Inc.

Among the 15 studies testing rifaximin in Irritable Bowel Syndrome, this one has the largest planned enrollment, is the only one that started in 2005, is one of 4 in phase 2, and was the 2nd registered.

Irritable Bowel Syndrome

1,119 studies on the registry are indexed under Irritable Bowel Syndrome; 210 are open to participants now.

Browse Irritable Bowel Syndrome studies →

Open to participants now

4 of the 15 studies testing rifaximin in Irritable Bowel Syndrome are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About rifaximin

Rifaximin: first FDA approval 2004 (XIFAXAN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 129 Irritable Bowel Syndrome studies recruiting now, 34 (26%) set no upper age limit and 85 (66%) stop at 75 or younger; 19 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing rifaximin in Irritable Bowel Syndrome, or all of them as a file.
02

Study summary

This is placebo-controlled study of three rifaximin doses in patients with DIBS. Subjects will be randomized to receive daily doses of placebo BID, rifaximin 275 mg BID, rifaximin 550 mg BID, or 1100 mg BID for 14 days. These four groups will subsequently receive an additional two weeks of placebo for a total of 4 weeks of treatment. A fifth group of subjects will receive rifaximin 550 mg BID for a period of 28 days. Subjects who successfully respond to treatment at the end of the 28-day Treatment Phase will be followed in a Post-treatment Phase that includes study visits during Weeks 6, 8, 12 and 16. Subjects who relapse during the Post-treatment Phase will be discontinued from the study.

Read the detailed description

While IBS is one of the most common chronic medical conditions the etiology of IBS is unknown. Although not a life-threatening illness, IBS is considered to be a serious condition that has a substantial impact on a subject's day-to-day function. IBS is characterized by abdominal pain and altered bowel habits, including diarrhea, constipation, or alternating diarrhea and constipation. Symptoms are typically intermittent but may be continuous.

03

Conditions studied

  • Irritable Bowel Syndrome

Keywords

  • Irritable bowel syndrome
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female subject 18 years of age or older.
  2. Irritable bowel syndrome confirmed by the Rome II Criteria
  3. Lower endoscopic examination that demonstrates normal colonic anatomy

Exclusion criteria

Exclusion Criteria:

  1. Subject has exclusively constipation-predominant IBS (CIBS) that is characterized by \< 3 bowel movements/week or hard and lumpy stools.
  2. Subject has alternating IBS, but is currently presenting with constipation associated IBS symptoms.
  3. Subject has had adequate control of their DIBS and their symptom of bloating the week preceding the screening visit or at the time of randomization. Bloating includes the following symptoms: abdominal fullness, bloating, gas, or swelling.
  4. Subjects has a positive stool culture for O \& P (ovum and parasite) and/or Clostridium difficile
  5. Subject has failed to record 2 negative weekly global assessments during the past 10 days prior to randomization.
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
525 participants (estimated)

Interventions

06

What researchers measure

Primary outcomes

  1. The primary objective of this trial is to evaluate the efficacy of a 14-day course of oral rifaximin at 550 mg BID versus placebo in providing adequate relief from Diarrhea-associated IBS (DIBS) symptoms.

Secondary outcomes

  1. To evaluate the dose-response relationship of placebo administered for 28 days and rifaximin administered at 275 mg BID, 550 mg BID, or 1100 mg BID for 14 days;

  2. to evaluate the efficacy of 550 mg BID for 4 weeks to determine if there are any differences when treatment is extended for an additional 2-week period when compared to a similar dosing regimen for 2 weeks;

  3. to evaluate the durability of response over a 12-week Post-treatment Phase in subjects with DIBS who achieved a response during the acute Treatment Phase of the study.

07

Study locations

67 sites
  • Mayo Clinic Scottsdale
    Scottsdale, Arizona 85259, United States
  • Premeire Pharmaceutical Research
    Tempe, Arizona 85282, United States
  • Advanced Clinical Research Institute
    Anaheim, California 92801, United States
  • Lovelace Scientific Resources
    Irvine, California 92618, United States
  • West Gastroenterology Medical Group
    Los Angeles, California 90045, United States
  • Beverly Hills Gastroenterology
    Los Angeles, California 90067, United States
  • Medical Associates Research Group
    San Diego, California 92123, United States
  • Gastroenterology Associates of Fairfield County
    Bridgeport, Connecticut 06606, United States
  • Connecticut Gastroenterology Institute
    Bristol, Connecticut 06010-0977, United States
  • Litchfield County Gastroenterology Associates, LLC
    Torrington, Connecticut 06790, United States
  • Clinical Research of West Florida
    Clearwater, Florida 33765, United States
  • University Clinical Research
    DeLand, Florida 32720, United States
  • Research Consultants Group
    Hialeah, Florida 33016, United States
  • Borland-Groover Clinic
    Jacksonville, Florida 32256, United States
  • Miami Research Associates
    Miami, Florida 33173, United States
  • Advanced Gastroenterology Associates
    Palm Harbor, Florida 34684, United States
  • Shafran Gastroenterology
    Winter Park, Florida 32789, United States
  • Florida Medical Clinic
    Zephyrhills, Florida 33542, United States
  • Rockford Gastroenterology
    Rockford, Illinois 61107, United States
  • Community Clinical Research Center
    Anderson, Indiana 46016, United States
  • Indianapolis Gastroenterology Research Foundation
    Indianapolis, Indiana 46237, United States
  • Gastrointestinal Clinic of Quad Citites
    Davenport, Iowa 52807, United States
  • University of Kansas Medical Center
    Kansas City, Kansas 66160-7350, United States
  • Digestive Disorders Associates
    Annapolis, Maryland 21401, United States
  • Chevy Chase Clinical Research
    Chevy Chase, Maryland 20815, United States
  • Washington County Hospital
    Hagerstown, Maryland 21740, United States
  • Maryland Clinical Trials
    Severna Park, Maryland 21146, United States
  • Capital Gastroenterology Consultants, PA
    Silver Springs, Maryland 20901, United States
  • Coastal Research Associates
    Braintree, Massachusetts 02184, United States
  • Henry Ford Hospital
    Chesterfield, Michigan 48047, United States
  • Gastrointestinal Associates, PA
    Jackson, Mississippi 39202, United States
  • Digestive Health Specialists, PA
    Tupelo, Mississippi 38801, United States
  • Gastroenterology and Hepatology
    Kansas City, Missouri 64131, United States
  • Center for Digestive & Liver Diseases, Inc.
    Mexico, Missouri 65265, United States
  • Specialist in Gastroenterology
    Saint Louis, Missouri 63141, United States
  • Gastroenterology Specialities
    Lincoln, Nebraska 68503, United States
  • Long Island Clinical Research
    Great Neck, New York 11021, United States
  • New York Center for Clinical Research
    Lake Success, New York 11042, United States
  • Asheville Gastroenterology Associates
    Asheville, North Carolina 28801, United States
  • University of North Carolina
    Chapel Hill, North Carolina 27579, United States
  • Charlotte Gastroenterology & Hepatology
    Charlotte, North Carolina 28207, United States
  • Vital re:Search
    Greensboro, North Carolina 27408, United States
  • Carolina Research
    Greenville, North Carolina 27834, United States
  • Bethany Medical Center
    High Point, North Carolina 27262, United States
  • East Carolina Gastroenterology
    Jacksonville, North Carolina 28546, United States
  • Wake Research Associates
    Raleigh, North Carolina 27612, United States
  • Rocky Mount, North Carolina 27804, United States
  • Hanover Medical Specialists, PA
    Wilmington, North Carolina 28401, United States
  • Consultants for Clinical Research
    Cincinnati, Ohio 45219, United States
  • Digestive Health Network
    Cincinnati, Ohio 45220, United States
  • GI & Liver Diseases Consultants
    Dayton, Ohio 45440, United States
  • Wells Institute for Health Awareness
    Kettering, Ohio 45429, United States
  • Oklahoma Foundation for Digestive Research
    Oklahoma City, Oklahoma 73104, United States
  • Digestive Health Specialists, PA
    Oklahoma City, Oklahoma 73112, United States
  • West Hills Gastroenterology Associates, PC
    Portland, Oregon 97225, United States
  • Columbia Gastroenterology Associates
    Columbia, South Carolina 29203, United States
  • ClinSearch
    Chattanooga, Tennessee 37404, United States
  • Regional Research Institute
    Jackson, Tennessee 38305, United States
  • Holston Valley Physicians
    Kingsport, Tennessee 37660, United States
  • Austin Gastroenterology
    Austin, Texas 78745, United States
  • Advanced Research Institute
    Ogden, Utah 84405, United States
  • University of Utah School of Medicine
    Salt Lake City, Utah 84132, United States
  • Internal Medicine Associates
    Danville, Virginia 24541, United States
  • Northwest Gastroenterology Associates
    Bellevue, Washington 98004, United States
  • North Pacific Clinical Research
    Redmond, Washington 98052, United States
  • Spokane Digestive Disease Center
    Spokane, Washington 99204, United States
  • Wisconsin Center for Advanced Research
    Milwaukee, Wisconsin 53215, United States
08

References and documents

Publications

  • Schoenfeld P, Pimentel M, Chang L, Lembo A, Chey WD, Yu J, Paterson C, Bortey E, Forbes WP. Safety and tolerability of rifaximin for the treatment of irritable bowel syndrome without constipation: a pooled analysis of randomised, double-blind, placebo-controlled trials. Aliment Pharmacol Ther. 2014 May;39(10):1161-8. doi: 10.1111/apt.12735. Epub 2014 Apr 3. PubMed 24697851 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2005, a primary completion of Aug 2007 and a completion of Sep 2008. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 22, 2005
First posted
Dec 23, 2005
Start
Dec 2005
Primary completionActual
Aug 2007
CompletionActual
Sep 2008
Last update
Nov 25, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 25, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00269412
First posted
Dec 23, 2005
Start date
Dec 2005
Primary completion
Aug 2007
Completion
Sep 2008
Last update
Nov 25, 2019
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rifaximin

Start the discussion